Skip to content

The AI Prognostic Assessment and Pathological Basis Research of Early HCC After Minimally Invasive Treatment

The Artificial Intelligent Prognostic Assessment and Pathological Basis Research of Early Primary Hepatocellular Carcinoma After Minimally Invasive Treatment Based on Multimodal MRI and Clinical Big Data

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04299919
Enrollment
1200
Registered
2020-03-09
Start date
2007-04-01
Completion date
2024-06-30
Last updated
2020-03-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular Carcinoma

Keywords

Precision medicine information processing, Lesion recognition, Feature extraction, Deep learning, Diagnosis model

Brief summary

The study evaluates artificial intelligence method based on multimodal magnetic resonance imaging (MRI) images and clinical data in preoperative prediction of prognosis in early hepatocellular carcinoma (HCC) patients treated with minimally invasive treatment. The correlation between prognosis-related MRI features and pathological features was studied through artificial intelligence method, so as to provide the interpretability of image features for predicting the prognosis of HCC patients treated with minimally invasive treatment.

Detailed description

The prognosis prediction of early stage hepatocellular carcinoma (HCC) after minimally invasive treatment involves clinical decision of treatment and follow-up. Magnetic resonance imaging (MRI) has become the main approach for monitoring and following up of HCC, however it's difficult to predict HCC prognosis before surgery. We found the following limitations among previous researches: multimodal MRI using different sequences shows uncertain boundaries of HCC, which makes precise segmentation more difficult, and also leads to an additional workload for extracting high throughput radiomics features, which are limited in quantity and repeatability. Regarding to prognosis aspect, the MRI images, clinical data, and follow up information have not been fully exploited yet. In addition, the prognosis result obtained by radiomics workflow is difficult to be explained and applied to clinical application. Therefore, we conduct a study to solve the problems mentioned above: (1) To explore an effective deep learning neural network method and a pre-training model for improving tumor segmentation accuracy. (2) To establish a method for extracting high-throughput multi-dimensional and multimodal MRI radiomics features related to HCC prognosis. (3) To explore a correlation between multimodal MRI based pathological features of early stage HCC and the results of multimodal MRI based prognosis depth network of early stage HCC after minimally invasive treatment. Based on above approaches, we aim to establish multimodal MRI based prognosis model of early stage HCC after minimally invasive treatment in different clinical application scenarios guiding to clinical decision-making. Moreover, we also aim to explore the correlation between MRI radiomics features and pathology, which provides theoretical foundations for the MRI radiomics based pathological researches.

Interventions

PROCEDUREMinimally invasive treatment

All hepatocellular carcinoma (HCC) patients received minimally invasive treatment, including transcatheter arterial chemoembolization (TACE), radiofrequency ablation (RFA) or combined.

PROCEDUREHepatectomy

All hepatocellular carcinoma (HCC) patients received hepatectomy.

Sponsors

The First Affiliated Hospital of Dalian Medical University
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Hepatocellular carcinoma patients received minimally invasive treatment (transcatheter arterial chemoembolization, radiofrequency ablation, or combined) or hepatectomy; * Patients received MRI examination within 1 month before treatment; * Complete post-treatment prognosis information.

Exclusion criteria

* local or systemic treatment before MR examination; * Incomplete clinical and pathological data; * Heavy image artifacts.

Design outcomes

Primary

MeasureTime frameDescription
Three-month recurrenceThree monthsAll HCC patients have been regularly monitored for recurrence via contrast CT or MRI for at least three months.
Six-month recurrenceSix monthsAll HCC patients have been regularly monitored for recurrence via contrast CT or MRI for at least six months.
One-year recurrenceOne yearAll HCC patients have been regularly monitored for recurrence via contrast CT or MRI for at least one year.
Two-year recurrenceTwo yearsAll HCC patients have been regularly monitored for recurrence via contrast CT or MRI for at least two years.
Three-year recurrenceThree yearsAll HCC patients have been regularly monitored for recurrence via contrast CT or MRI for at least three years.

Secondary

MeasureTime frameDescription
Progression-free survivalThree months, six months, one year, two years, and three years.The time between the tumor progression and initial treatment was recorded.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026